NCT00953498View on ClinicalTrials.gov

Influence of Glitazones on the Vasodilatory Effect of High-density Lipoprotein (HDL) Lipoproteins

PHASE4CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

October 31, 2007

Primary Completion Date

March 31, 2012

Study Completion Date

March 31, 2012

Conditions
Type 2 Diabetes
Interventions
DRUG

pioglitazone

After randomization, patients will be treated by pioglitazone or rosiglitazone

DRUG

rosiglitazone

treatment with rosiglitazone at a dose between 4mg and 8 mg/day

Trial Locations (1)

21000

Service Endocrinologie-diabétologie, Hôpital du Bocage CHU, Dijon

All Listed Sponsors
lead

Centre Hospitalier Universitaire Dijon

OTHER

NCT00953498 - Influence of Glitazones on the Vasodilatory Effect of High-density Lipoprotein (HDL) Lipoproteins | Biotech Hunter | Biotech Hunter